<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordOutput xmlns:ns2="local" id="272640"><TitleDisplay>Intravenous Lidocaine Versus Morphine for Severe Pain in the ED</TitleDisplay><TitleOfficial>Intravenous Lidocaine Versus Provider Chosen Dose of Morphine for the Treatment of Severe Pain in the Emergency Department: An Open-label, Randomized, Controlled, Pilot Study</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02912195</Identifier><Identifier type="Organisational Study">00001</Identifier></Identifiers><Indications><Indication id="20">Pain</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>lidocaine</Name><Drug id="44403">lidocaine</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>morphine</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44403">lidocaine</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1085064">Alameda Health System</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="44403" type="Drug"><TargetEntity id="91302" type="siDrug">Lidocaine hydrochloride</TargetEntity></SourceEntity><SourceEntity id="1085064" type="Company"><TargetEntity id="5026182084" type="organizationId">Alameda Health System</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"></TargetEntity><TargetEntity id="D010146" type="MeSH"></TargetEntity><TargetEntity id="-1585850437" type="omicsDisease"></TargetEntity><TargetEntity id="1" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1085064">Alameda Health System</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="1669">Local anesthetic</Class><Class id="59620">Unspecified drug target</Class></Class><Technologies><Technology id="615">Aerosol formulation dermatological</Technology><Technology id="611">Dermatological formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="776">Oral gel formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="745">Suspension</Technology><Technology id="558">Transdermal formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>32</PatientCountEnrollment><DateStart>2016-03-31T00:00:00Z</DateStart><DateEnd type="actual">2016-09-30T00:00:00Z</DateEnd><DateChangeLast>2018-06-02T04:22:16Z</DateChangeLast><DateAdded>2016-09-29T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Alameda Health System, Highland Hospital</Affiliation><Name>Andrew Herring, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Subject has severe pain (NRS &gt;/= 7)&lt;/li&gt;&lt;li&gt;Subject has anticipated ED stay of &gt;/= 1 h&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;High acuity trauma patients&lt;/li&gt;&lt;li&gt;Patients deemed to critically ill by ED provider&lt;/li&gt;&lt;li&gt;Active psychosis&lt;/li&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;li&gt;History of heart block or bradycardia&lt;/li&gt;&lt;li&gt;Allergy to lidocaine or amide type local anesthetic&lt;/li&gt;&lt;li&gt;History of seizures&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Pain score (NRS 0 to 10)</Description><Timeframe>At 60 minutes</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Adverse events: participants will be observed for the following adverse events and side effects: seizure, bradyarrhythmias, hyper or hypotension, perioral numbness, tinnitus, metallic taste, other, hypotension, hypoxia, nausea, vomiting, itching, or other side effects. Participants have the opportunity to report other side effects during the study</Description><Timeframe>0-60 minutes</Timeframe></Measure><Measure><Description>Pain relief: pain NRS at 0 min minus pain NRS at 50 min</Description><Timeframe>At 50 minutes</Timeframe></Measure><Measure><Description>Pain relief: pain NRS at 0 min minus pain NRS at 60 min</Description><Timeframe>At 60 minutes</Timeframe></Measure><Measure><Description>Pain score (NRS 0 to 10)</Description><Timeframe>At 10 minutes</Timeframe></Measure><Measure><Description>Pain score (NRS 0 to 10)</Description><Timeframe>At 20 min</Timeframe></Measure><Measure><Description>Pain score (NRS 0 to 10)</Description><Timeframe>At 30 min</Timeframe></Measure><Measure><Description>Pain score (NRS 0 to 10)</Description><Timeframe>At 40 min</Timeframe></Measure><Measure><Description>Pain score (NRS 0 to 10)</Description><Timeframe>At 50 min</Timeframe></Measure><Measure><Description>Pain relief: pain NRS at 0 min minus pain NRS at 10 min</Description><Timeframe>At 10 min</Timeframe></Measure><Measure><Description>Pain relief: pain NRS at 0 min minus pain NRS at 40 min</Description><Timeframe>At 40 min</Timeframe></Measure><Measure><Description>Pain relief: pain NRS at 0 min minus pain NRS at 20 min</Description><Timeframe>At 20 min</Timeframe></Measure><Measure><Description>Pain relief: pain NRS at 0 min minus pain NRS at 30 min</Description><Timeframe>At 30 min</Timeframe></Measure><Measure><Description>Patient satisfaction: the proportion of patients saying, 'yes' to 'would you have this pain medication again for similar pain?'</Description><Timeframe>60 min</Timeframe></Measure><Measure><Description>Proportion requiring rescue medications: the proportion of patients requiring rescue intravenous morphine at 20 and 40 min</Description><Timeframe>At 20 and 40 min</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;Objective of this open-label, randomized, controlled, pilot trial was to evaluate the analgesic efficacy of intravenous (IV) &lt;ulink linkType="Drug" linkID="44403"&gt;lidocaine&lt;/ulink&gt; versus provider      chosen dose of intravenous morphine for the treatment of severe pain in the emergency department.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Investigators      and research assistants would recruit patients &gt;/= 18 years old with severe pain (NRS &gt;/= 7) and an      anticipated stay in the emergency department &gt;/= 1 h. A sample size calculation would be      performed and 32 patients would be enrolled.&lt;/para&gt;&lt;para&gt;Intervention: after a trained research assistant obtains written informed consent, eligible      patients would be randomized to the intravenous lidocaine or morphine arms of the study.      In the intravenous lidocaine arm, patients would receive iv lidocaine (75 mg if &amp;lt; 50 kg, 100 mg      if 50 to 100 kg, and 150 mg if &amp;gt; 100 kg) over 10 min in a 100 ml normal saline minibag      followed by a 50 min iv lidocaine drip (75 mg if &amp;lt; 50 kg, 100 mg if 50 to 100 kg, and 150 mg      if &amp;gt; 100 kg). In the morphine arm, the ED provider would choose an appropriate dose of      morphine for the patient. At 20 and 40 min, the patients would be asked 'would you      like additional pain medication?' Patients responding in the affirmative would receive      morphine 4 mg iv.&lt;/para&gt;&lt;para&gt;Data collection: the trained research assistant would collect data on the patients' pain      scores, side effects, and rescue morphine.&lt;br/&gt;Statistical analysis: investigators would perform descriptive statistics and compare pain      scores and pain relief at each time point with unpaired t-tests.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Alameda Health System, Highland Hospital</Name><Address1>Oakland</Address1><Address2>California</Address2><Address3>94602</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02912195</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25875">Based on Numerical Rating Scale [NRS]</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25875">Based on Numerical Rating Scale [NRS]</SubEndpoint><SubEndpoint disease="Pain" id="42998">Based on Time to pain freedom and onset of pain relief</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="25929"><Endpoint>Assessment of Procedural Analgesia/Anesthesia</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26033"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26038"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26044">Assessment of analgesic use/rescue medication</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="34784"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="35228">Assessment of patient satisfaction</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22091"><Criterion>Subjects by disease severity</Criterion><SubCriteria><SubCriterion disease="Pain" id="22094">Subjects with severe pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22148"><Criterion>Subjects Based on Pain Scale Ratings</Criterion><SubCriteria><SubCriterion disease="Pain" id="22150">Based on Numerical Rating Scale [NRS]</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22262"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Pain" id="34371"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="22263">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="20052"><Criterion>Subjects with Somatic Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="20058">Subjects with trauma related pain</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20115"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Pain" id="20182"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Pain" id="20186">Protocol specified exclusion criteria for women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="24893"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Pain" id="20129">Hypersensitivity/ contraindication to investigational drug/procedure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="26300"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Pain" id="20108">Subjects with abnormal/unacceptable cardiac function</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2016-09-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="estimated">2016-09-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>6.03 Months</EnrollmentPeriod><EnrollmentRate>5.31 Patients/Month</EnrollmentRate><DateFirstReceived>2016-09-20T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-09-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2016-11-21T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordOutput>